Precision medicine: lessons learned from the SHIVA trial
Precision medicine: lessons learned from the SHIVA trial
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
[...]many patients had hormone receptor abnormalities; response to hormone monotherapy in pretreated patients with advanced disease is unlikely.3 Fourth, some matches were incorrect: imatinib, an ineffective RET inhibitor (IC50 37 μmol/L) was matched to RET alterations.4 Fifth, precision medicine is defined by the presence of biological data showi...
Alternative Titles
Full title
Precision medicine: lessons learned from the SHIVA trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751217828
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751217828
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(15)00397-6
